Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
19 hedge funds and large institutions have $715K invested in Statera Biopharma, Inc. Common Stock in 2015 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
6% more funds holding
Funds holding: 18 → 19 (+1)
2% more capital invested
Capital invested by funds: $699K → $715K (+$15.8K)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$81.5K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$48.6K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$22K |
| 4 |
TDC
Thompson Davis & Co
Richmond,
Virginia
|
+$7.32K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$1.73K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$71K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$47.3K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$24.9K |
| 4 |
Morgan Stanley
New York
|
-$17.6K |
| 5 |
Citigroup
New York
|
-$7K |
STAB Hedge Fund Activity: Q3 2015 in Review
19 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q3 2015, worth a combined $715K — up 2.3% from $699K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new STAB positions and 2 closed out — a net gain of 1 holder — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Ladenburg Thalmann Financial Services, adding an estimated $81.5K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $71K sold.
- 19 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q3 2015, up from 18 in Q2 2015.
- Funds reported $715K of Statera Biopharma, Inc. Common Stock stock for Q3 2015, up 2.3% quarter-over-quarter.
- 3 funds opened new Statera Biopharma, Inc. Common Stock positions in Q3 2015 and 2 closed out, a net change of +1 holder.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q3 2015 was Ladenburg Thalmann Financial Services, an estimated $81.5K added.
- The largest Statera Biopharma, Inc. Common Stock seller in Q3 2015 was Renaissance Technologies, an estimated $71K sold.
Based on aggregated 13F filings for Q3 2015.